Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: November 29, 2013
Reporting Period: The filing serves as a notice of the submission of unaudited interim consolidated financial statements and a Board of Directors report for the period ended September 30, 2013, originally filed in Israel on November 28, 2013.
Key Financial Metrics
The provided text is a cover sheet and exhibit index for the Form 6-K. It does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. These metrics are contained within the attached exhibits (99.1 and 99.2) which are incorporated by reference but not detailed in this text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the submission of the interim financial statements and the Board's report on the state of the business for the period ended September 30, 2013.
Guidance, Outlook, and Risks
Management Commentary: The filing references a "Board of Directors Report on the State of the Company's Business" (Exhibit 99.3) but does not summarize its contents, guidance, or outlook in this text.
Risks and Contingencies: No specific risks or contingencies are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 for the full unaudited interim consolidated financial statements as of September 30, 2013.
- Review Exhibit 99.2 for specific financial data extracted from the interim statements.
- Review Exhibit 99.3 for the Board of Directors' report on the state of the business, which likely contains operational updates and strategic outlook.
- Verify the translation accuracy of the attached exhibits, as the original filings were made in Israel.